Fig. 7 | Signal Transduction and Targeted Therapy

Fig. 7

From: O-GlcNAcylation of YTHDF2 promotes HBV-related hepatocellular carcinoma progression in an N6-methyladenosine-dependent manner

Fig. 7

Targeting OGT-meditated YTHDF2 O-GlcNAcylation suppresses HBV-associated hepatocarcinogenesis in vivo. a Schematics showing experimental procedures of DEN-induced HBV-transgenic (Tg) mice. b Gross appearances of liver samples with tumors. c, d Tumor nodules numbers (c) and liver/body weight (d) of HBV-Tg mice, n = 6/group. e, f ALT (e) and AST (f) levels in mouse serum samples, n = 6/group. g Representative images of immunohistochemical (IHC) staining of indicated proteins in the liver of HBV-Tg mice and quantification of IHC by using Image J (n = 6/group), bar = 100 μm. h The indicated proteins expression and YTHDF2 O-GlcNAcylation level in liver tumors of HBV-Tg mice by immunoblots analysis and sWGA pull-down assay. i, j Kaplan–Meier survival analysis of YTHDF2 and MCM2 (i) or YTHDF2 and MCM5 (j) depicting the overall survival (OS) of patients with HCC from the TCGA-LIHC cohort, P < 0.0001. Data are represented as mean ± SD. For c–g, data were analyzed by one-way ANOVA followed by the Tukey’s test, **P < 0.01, ***P < 0.001

Back to article page